UBS ETRACS Alerian MLP Index ETN Series B Financials

AMUB

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows UBS ETRACS Alerian MLP Index ETN Series B (AMUB) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI AMUB FY2025 2026-04-22

Profitability here is a leverage story: a vast asset base produces thin returns, and cash generation only recently recovered.

The key shift is cash conversion: operating cash flow moved from -$27.1B in FY2024 to $24.6B in FY2025, so reported profit once again showed up as cash rather than being offset elsewhere on the balance sheet. But capital still ran down because dividends of $13B were far above net income of $3.6B, which helps explain why equity fell and retained earnings slipped below zero.

Return spread matters more than margin here: FY2025 return on assets was only 0.2% while return on equity was 4.0%, showing that shareholder returns depended mainly on leverage. With a 17.1x liabilities-to-equity posture, even small changes in asset profitability can have an outsized effect on common equity.

Cash looks huge in absolute terms at $231B, but against $1.6T of assets it functions as operating liquidity inside a very large funded balance sheet, not as surplus cash. The more revealing signal is financing outflow despite positive operations: financing cash flow was -$33.8B even with $24.6B of operating inflow, so FY2025 leaned less on external funding than the prior two years.

Financial Health Signals

Financial Profile 14/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of UBS ETRACS Alerian MLP Index ETN Series B's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Growth

UBS ETRACS Alerian MLP Index ETN Series B's revenue grew 12.7% year-over-year to $47.7B, a solid pace of expansion. This earns a growth score of 65/100.

Leverage

UBS ETRACS Alerian MLP Index ETN Series B has elevated debt relative to equity (D/E of 17.13), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 0/100, reflecting increased financial risk.

Returns

UBS ETRACS Alerian MLP Index ETN Series B generates a 4.0% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 19/100. This is up from 1.6% the prior year.

Piotroski F-Score Neutral

6/9

UBS ETRACS Alerian MLP Index ETN Series B passes 6 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Cash-Backed

6.89x

For every $1 of reported earnings, UBS ETRACS Alerian MLP Index ETN Series B generates $6.89 in operating cash flow ($24.6B OCF vs $3.6B net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$47.7B

YoY+12.7%

UBS ETRACS Alerian MLP Index ETN Series B generated $47.7B in revenue in fiscal year 2025. This represents an increase of 12.7% from the prior year.

EBITDA

N/A

Net Income

$3.6B

YoY+132.6%

UBS ETRACS Alerian MLP Index ETN Series B reported $3.6B in net income in fiscal year 2025. This represents an increase of 132.6% from the prior year.

EPS (Diluted)

N/A

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$231.0B

YoY-5.1%

UBS ETRACS Alerian MLP Index ETN Series B held $231.0B in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

3.86B

YoY+0.0%

UBS ETRACS Alerian MLP Index ETN Series B had 3.86B shares outstanding in fiscal year 2025. This represents an increase of 0.0% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

7.5%

YoY+3.9pp

UBS ETRACS Alerian MLP Index ETN Series B's net profit margin was 7.5% in fiscal year 2025, showing the share of revenue converted to profit. This is up 3.9 percentage points from the prior year.

Return on Equity

4.0%

YoY+2.4pp

UBS ETRACS Alerian MLP Index ETN Series B's ROE was 4.0% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 2.4 percentage points from the prior year.

Capital Allocation

R&D Spending

N/A

Share Buybacks

N/A

Capital Expenditures

N/A

AMUB Income Statement

Metric	FY25	FY24	FY23	FY22	FY21
Revenue	$47.7B+12.7%	$42.3B+25.7%	$33.7B-3.6%	$34.9B-2.5%	$35.8B
Cost of Revenue	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	N/A	N/A	N/A	N/A	N/A
Operating Income	N/A	N/A	N/A	N/A	N/A
Interest Expense	$135.0M+2.3%	$132.0M+36.1%	$97.0M+10.2%	$88.0M-10.2%	$98.0M
Income Tax	$534.0M-40.7%	$900.0M-25.4%	$1.2B-34.6%	$1.8B-3.1%	$1.9B
Net Income	$3.6B+132.6%	$1.5B-53.8%	$3.3B-53.4%	$7.1B+0.8%	$7.1B
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q2'25	Q1'25	Q4'24	Q2'24	Q1'24	Q4'23	Q2'23
Revenue	N/A	$11.6B-4.3%	$12.2B	N/A	$9.9B+8.7%	$9.1B	N/A	$8.5B
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	N/A	$37.0M+5.7%	$35.0M	N/A	$29.0M+31.8%	$22.0M	N/A	$25.0M
Income Tax	N/A	-$336.0M-210.9%	$303.0M	N/A	$28.0M-92.3%	$366.0M	N/A	$332.0M
Net Income	N/A	$1.2B+15.7%	$1.0B	N/A	-$224.0M-122.1%	$1.0B	N/A	$1.1B
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

AMUB Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21
Total Assets	$1.6T+3.1%	$1.6T+35.6%	$1.2T+4.6%	$1.1T-1.0%	$1.1T
Current Assets	N/A	N/A	N/A	N/A	N/A
Cash & Equivalents	$231.0B-5.1%	$243.4B+27.8%	$190.5B-2.4%	$195.2B-6.0%	$207.8B
Inventory	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A
Goodwill	$6.6B+1.5%	$6.5B+8.3%	$6.0B-4.3%	$6.3B-1.7%	$6.4B
Total Liabilities	$1.5T+3.7%	$1.5T+33.9%	$1.1T+5.0%	$1.0T-0.9%	$1.1T
Current Liabilities	N/A	N/A	N/A	N/A	N/A
Long-Term Debt	N/A	N/A	N/A	N/A	N/A
Total Equity	$89.2B-5.8%	$94.7B+70.4%	$55.6B-2.4%	$56.9B-2.6%	$58.4B
Retained Earnings	-$2.1B-127.4%	$7.8B-72.2%	$28.2B-11.1%	$31.7B+13.7%	$27.9B

Metric	Q4'25	Q2'25	Q1'25	Q4'24	Q2'24	Q1'24	Q4'23	Q2'23
Total Assets	$1.6T-3.3%	$1.7T+8.0%	$1.5T-1.3%	$1.6T+0.2%	$1.6T+40.1%	$1.1T-3.4%	$1.2T0.0%	$1.2T
Current Assets	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cash & Equivalents	$231.0B-10.6%	$258.3B	N/A	$243.4B-12.3%	$277.5B	N/A	$190.5B+5.3%	$181.0B
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	$6.6B-2.3%	$6.8B+0.9%	$6.7B+2.9%	$6.5B-7.4%	$7.0B+12.6%	$6.2B+4.0%	$6.0B-4.5%	$6.3B
Total Liabilities	$1.5T-3.1%	$1.6T+8.7%	$1.5T-1.6%	$1.5T+0.2%	$1.5T+38.5%	$1.1T-3.5%	$1.1T+5.5%	$1.0T
Current Liabilities	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$89.2B-6.0%	$94.9B-2.3%	$97.1B+2.6%	$94.7B+0.4%	$94.2B+70.2%	$55.4B-0.4%	$55.6B+4.3%	$53.3B
Retained Earnings	-$2.1B-158.0%	$3.7B-59.4%	$9.1B+16.5%	$7.8B+5.7%	$7.4B-74.6%	$29.2B+3.5%	$28.2B+1.5%	$27.8B

AMUB Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21
Operating Cash Flow	$24.6B+190.8%	-$27.1B+4.0%	-$28.2B-365.3%	$10.6B-65.2%	$30.6B
Capital Expenditures	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	-$22.3B-118.2%	$122.4B+2585.9%	-$4.9B+59.9%	-$12.3B-560.4%	-$1.9B
Financing Cash Flow	-$33.8B-5.1%	-$32.1B-263.2%	$19.7B+474.5%	-$5.3B-148.1%	$10.9B
Dividends Paid	$13.0B+333.3%	$3.0B-50.0%	$6.0B+42.9%	$4.2B-7.5%	$4.5B
Share Buybacks	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q2'25	Q1'25	Q4'24	Q2'24	Q1'24	Q4'23	Q2'23
Operating Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

AMUB Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21
Gross Margin	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A
Net Margin	7.5%+3.9pp	3.6%-6.2pp	9.8%-10.5pp	20.4%+0.7pp	19.7%
Return on Equity	4.0%+2.4pp	1.6%-4.4pp	6.0%-6.5pp	12.5%+0.4pp	12.1%
Return on Assets	0.2%+0.1pp	0.1%-0.2pp	0.3%-0.4pp	0.6%+0.0pp	0.6%
Current Ratio	N/A	N/A	N/A	N/A	N/A
Debt-to-Equity	17.13+1.6	15.56-4.2	19.80+1.4	18.41+0.3	18.10
FCF Margin	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q2'25	Q1'25	Q4'24	Q2'24	Q1'24	Q4'23	Q2'23
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	10.3%+1.8pp	8.5%	N/A	-2.3%-13.4pp	11.1%	N/A	13.3%
Return on Equity	N/A	1.3%+0.2pp	1.1%	N/A	-0.2%-2.1pp	1.8%	N/A	2.1%
Return on Assets	N/A	0.1%0.0pp	0.1%	N/A	-0.0%-0.1pp	0.1%	N/A	0.1%
Current Ratio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Debt-to-Equity	17.13+0.5	16.63+1.7	14.93-0.6	15.56-0.0	15.60-3.6	19.17-0.6	19.80+0.2	19.58
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Frequently Asked Questions

What is UBS ETRACS Alerian MLP Index ETN Series B's annual revenue?

UBS ETRACS Alerian MLP Index ETN Series B (AMUB) reported $47.7B in total revenue for fiscal year 2025. This represents a 12.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is UBS ETRACS Alerian MLP Index ETN Series B's revenue growing?

UBS ETRACS Alerian MLP Index ETN Series B (AMUB) revenue grew by 12.7% year-over-year, from $42.3B to $47.7B in fiscal year 2025.

Is UBS ETRACS Alerian MLP Index ETN Series B profitable?

Yes, UBS ETRACS Alerian MLP Index ETN Series B (AMUB) reported a net income of $3.6B in fiscal year 2025, with a net profit margin of 7.5%.

What is UBS ETRACS Alerian MLP Index ETN Series B's net profit margin?

UBS ETRACS Alerian MLP Index ETN Series B (AMUB) had a net profit margin of 7.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is UBS ETRACS Alerian MLP Index ETN Series B's return on equity (ROE)?

UBS ETRACS Alerian MLP Index ETN Series B (AMUB) has a return on equity of 4.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is UBS ETRACS Alerian MLP Index ETN Series B's operating cash flow?

UBS ETRACS Alerian MLP Index ETN Series B (AMUB) generated $24.6B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are UBS ETRACS Alerian MLP Index ETN Series B's total assets?

UBS ETRACS Alerian MLP Index ETN Series B (AMUB) had $1.6T in total assets as of fiscal year 2025, including both current and long-term assets.

How many shares does UBS ETRACS Alerian MLP Index ETN Series B have outstanding?

UBS ETRACS Alerian MLP Index ETN Series B (AMUB) had 3.86B shares outstanding as of fiscal year 2025.

What is UBS ETRACS Alerian MLP Index ETN Series B's debt-to-equity ratio?

UBS ETRACS Alerian MLP Index ETN Series B (AMUB) had a debt-to-equity ratio of 17.13 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is UBS ETRACS Alerian MLP Index ETN Series B's return on assets (ROA)?

UBS ETRACS Alerian MLP Index ETN Series B (AMUB) had a return on assets of 0.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is UBS ETRACS Alerian MLP Index ETN Series B's Piotroski F-Score?

UBS ETRACS Alerian MLP Index ETN Series B (AMUB) has a Piotroski F-Score of 6 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are UBS ETRACS Alerian MLP Index ETN Series B's earnings high quality?

UBS ETRACS Alerian MLP Index ETN Series B (AMUB) has an earnings quality ratio of 6.89x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is UBS ETRACS Alerian MLP Index ETN Series B?

UBS ETRACS Alerian MLP Index ETN Series B (AMUB) scores 14 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.